What happened with BDSX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Physicians use Biodesix’s tests at two points in lung care. When a patient has a suspicious lung nodule, Nodify CDT and Nodify XL2 help assess whether it may be cancerous. After a lung cancer diagnosis, GeneStrat tests identify tumor mutations and VeriStrat profiles the patient’s immune response to help guide treatment. Biodesix analyzes blood samples and returns results to healthcare providers, billing Medicare, commercial insurers, medical facilities or patients. This diagnostic testing accounts for most of its revenue.
Its smaller Development Services business serves biopharmaceutical, life sciences, diagnostic and research customers. These customers pay for work ranging from finding biological markers and developing tests to analyzing clinical-trial samples and supporting regulatory submissions and commercialization, under agreements tied to results, milestones or a service period.
The main testing business depends on physicians ordering tests and insurers covering and paying for them. Medicare supplies a substantial share of total revenue, making its coverage decisions and payment rates particularly important. Biodesix must also maintain CLIA laboratory certification and applicable licenses to perform testing and receive payment from government healthcare programs and many private insurers.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Beyond this list, Biodesix faces Foundation Medicine in tumor profiling and relies on Freenome’s U.S. operations as its sole supplier of Nodify CDT materials.
Guardant Health competes with Biodesix’s GeneStrat blood tests that help physicians choose lung-cancer treatment, and for testing work paid for by biopharmaceutical companies. Watch its oncology and biopharma testing revenue rather than its screening business for the overlap with Biodesix.
Veracyte competes with Biodesix in lung diagnostics, with a test in development that could challenge Nodify’s assessment of whether suspicious lung nodules are cancerous. Its main test revenue comes from prostate and thyroid testing, so lung-test development is the more relevant news for Biodesix holders.
bioAffinity Technologies’ sputum-based CyPath Lung competes with Biodesix’s Nodify blood tests to help physicians assess whether suspicious lung nodules are cancerous. CyPath Lung testing revenue is the relevant line to watch, rather than bioAffinity’s total revenue, which also includes pathology services.
Tempus AI and Biodesix sell cancer molecular testing to healthcare providers and compete for biopharmaceutical companies’ tumor-profiling and clinical-trial testing work. Tempus’s testing services for those drug developers are the clearest overlap with Biodesix’s Development Services, rather than its broader data-licensing business.
Caris Life Sciences overlaps with Biodesix in selling blood-based tumor tests that help physicians select cancer treatment and molecular testing services to biopharmaceutical companies. Its Caris Assure blood test and biopharma testing work are the offerings to watch alongside Biodesix’s GeneStrat and Development Services.
NeoGenomics competes with Biodesix for clinicians’ cancer-testing business and biopharmaceutical companies’ tumor-profiling and clinical-trial testing contracts. It provides laboratory testing and expert interpretation to pathology and oncology practices; its pharmaceutical-customer work is the closer comparison for Biodesix’s Development Services.
Biodesix depends on Bio-Rad for the core technology, equipment and reagents used to detect cancer mutations in GeneStrat’s droplet digital PCR testing; a supply disruption could affect testing until alternatives are validated. The partners are also developing additional oncology tests, making supply continuity and validation of the ddPLEX ESR1 assay relevant news for Biodesix’s clinical and biopharmaceutical services.
BillionToOne’s Northstar blood tests compete with Biodesix’s GeneStrat for physicians choosing treatment for advanced solid tumors, including lung cancer. Its oncology sales expansion is the relevant development to watch, separate from its UNITY prenatal-testing business.
Personalis competes with Biodesix for biopharmaceutical companies paying to profile cancer-related immune responses, discover biomarkers and test clinical-trial samples. Its drug-development testing work is the relevant comparison for Biodesix’s Development Services, rather than its physician-facing tests for residual or recurrent cancer.
Adaptive Biotechnologies competes with Biodesix for biopharmaceutical immune-profiling work, not primarily for lung-cancer clinical testing. Its Immune Medicine business analyzes immune-cell receptors, while its clonoSEQ clinical tests measure cancer remaining in blood-cancer patients; watch the former for the closer overlap with Biodesix’s Development Services.
NeoGenomics, Inc. earningsNEO
NeoGenomics' report can show whether drug developers are buying testing services, work that also supplies contracts for Biodesix's Development Services.
Look for NeoGenomics' pharmaceutical-customer testing revenue or contract activity, and compare it with Biodesix's Development Services revenue. Stronger activity would suggest drug developers are still commissioning tests, a supportive backdrop for Biodesix's bids; weaker activity would point to softer demand or tougher competition, but the companies have different customer mixes, so it would not prove Biodesix's revenue moved the same way.
Fed Interest Rate Decision
For Biodesix, the Fed’s decision on its policy rate matters because higher short-term rates can raise interest paid on its $50 million Perceptive loan, while lower rates can reduce it.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can lift interest expense on Biodesix’s loan, leaving less cash from its testing and services revenue to fund operations and growth.
If it comes in below expectations
Lower rates can reduce interest expense on Biodesix’s loan, leaving more cash from its testing and services revenue available for operations and growth.
Biodesix, Inc. earningsThis company
Biodesix's report will show whether revenue from its lung tests can keep growing and hold overall gross margin as operating expenses rise.
Read Diagnostic Tests revenue alongside Development Services revenue and overall gross margin. If diagnostic-test revenue grows while gross margin holds or improves, Biodesix is turning demand and reimbursement into more gross profit. If growth comes mainly from more volatile Development Services, or gross margin falls as revenue rises, the core testing business is not yet offsetting cost pressure.
BillionToOne, Inc. earningsBLLN
BillionToOne's report will show how its Northstar oncology tests are selling, a read-through on the physician testing market shared with Biodesix's GeneStrat.
Read BillionToOne's oncology-test sales and expansion alongside the trend in Biodesix's Diagnostic Tests revenue. Stronger Northstar sales would show physicians are adopting this type of blood test and that GeneStrat faces a more compelling alternative; weak sales could signal slower uptake, but the products and customer bases differ, so BillionToOne's sales are not a direct count of Biodesix orders.
Bio-Rad Laboratories, Inc. earningsBIO
Bio-Rad's report matters because Biodesix's GeneStrat tests rely on its droplet digital PCR technology and reagents, though Bio-Rad's results alone cannot confirm supply to Biodesix.
Look for Bio-Rad disclosures about droplet digital PCR reagent supply, the related collaboration, or oncology assay progress. Reported continuity or advancing assay work would suggest no newly disclosed obstacle in this supply and development link; a disruption or stalled validation could mean delays or extra validation work for Biodesix's GeneStrat tests. If Bio-Rad does not mention Biodesix, that silence does not confirm uninterrupted supply.
bioAffinity Technologies, Inc. earningsBIAF
bioAffinity Technologies' report will show CyPath Lung testing revenue, a read-through on the lung-nodule assessment market shared with Biodesix's Nodify tests.
Read bioAffinity Technologies' CyPath Lung testing revenue alongside the trend in Biodesix's Diagnostic Tests revenue, keeping in mind that CyPath Lung uses sputum and Nodify uses blood. Stronger CyPath Lung revenue would show that another lung-nodule testing option is gaining use; weak revenue would show limited traction for that alternative, not that demand for Nodify is weak.
